Next-generation Sequencing Market Size, Share & Trends Analysis Report By Technology (Targeted Sequencing & Resequencing), By Application (Oncology, Consumer Genomics), By Workflow, By End-use, By Region, And Segment Forecasts, 2022 - 2030
This report can be delivered to the clients within 3 Business Days
Next-generation Sequencing Market Growth & Trends
The global next-generation sequencing market size is expected to reach USD 14.8 billion by 2030, registering a CAGR of 12.4% over the forecast period, according to a new report by Grand View Research, Inc. Next-generation Sequencing (NGS) is a parallel processing technique that can establish the sequence of nucleotides in a whole genome with scalability, ultra-high capacity, and fast speed. Furthermore, in the healthcare industry, NGS is gradually being incorporated into medical laboratory research, screening, and disease diagnoses. In personalized medicine, it has been frequently utilized to accelerate the drug research process.
Different potential sequencing methods such as RNA sequencing, whole-genome sequencing, and whole-exome and targeted sequencing amongst others are prominently used by researchers to get comprehensive sample analysis. When compared to the traditional Sanger sequencing technology, NGS is less expensive and provides higher throughput for DNA sequencing. The growing automation in the pre-sequencing protocols, post-sequencing protocols, and data analysis is also projected to have a positive impact on the NGS market. The utilization of novel platforms for the development of personalized medicine by medical analysis at a genetic level is also a significant factor, which is expected to enhance demand for NGS over the forecast period.
Besides, there are other significant growth trends that are being witnessed in the sequencing industry, such as the development of personalized medicine and companion diagnostics, growing advancements in cloud computing, and data integration. Furthermore, the easy availability of genomic and proteomic data has poised this market to exhibit potentially high-value avenues and opportunities for growth over the forecast period. The market growth is also being fueled by an increase in the global prevalence of cancer and the availability of sophisticated healthcare facilities. As per GLOBOCAN 2020, there have been 1,92,92,789 new cancer cases in 2020, with the number expected to rise to 2,88,87,940 by 2040. Such a substantial rise in the number of cancer cases is estimated to leverage cancer research which will eventually accelerate the NGS market growth.
The NGS diagnostic techniques have the potential to determine a virus's genomic sequence and aid scientists in their understanding of mutations. Furthermore, throughout the COVID-19 epidemic, governments across the globe have been collaborating with the corporate sector to introduce NGS technology to the market as a viable diagnostic tool. The US Food and Drug Administration granted Illumina Inc. a case of emergency use permit for the first COVID-19 diagnostic using the next-generation sequence technique in June 2020. The Illumina COVIDSeq Test for qualitative identification of SARS-CoV-2 RNA has been approved by the FDA. As a result, the usage of next-generation sequencing (NGS) technologies is projected to increase during the pandemic.
Next-generation Sequencing Market Report Highlights
Next-generation Sequencing Market Growth & Trends
The global next-generation sequencing market size is expected to reach USD 14.8 billion by 2030, registering a CAGR of 12.4% over the forecast period, according to a new report by Grand View Research, Inc. Next-generation Sequencing (NGS) is a parallel processing technique that can establish the sequence of nucleotides in a whole genome with scalability, ultra-high capacity, and fast speed. Furthermore, in the healthcare industry, NGS is gradually being incorporated into medical laboratory research, screening, and disease diagnoses. In personalized medicine, it has been frequently utilized to accelerate the drug research process.
Different potential sequencing methods such as RNA sequencing, whole-genome sequencing, and whole-exome and targeted sequencing amongst others are prominently used by researchers to get comprehensive sample analysis. When compared to the traditional Sanger sequencing technology, NGS is less expensive and provides higher throughput for DNA sequencing. The growing automation in the pre-sequencing protocols, post-sequencing protocols, and data analysis is also projected to have a positive impact on the NGS market. The utilization of novel platforms for the development of personalized medicine by medical analysis at a genetic level is also a significant factor, which is expected to enhance demand for NGS over the forecast period.
Besides, there are other significant growth trends that are being witnessed in the sequencing industry, such as the development of personalized medicine and companion diagnostics, growing advancements in cloud computing, and data integration. Furthermore, the easy availability of genomic and proteomic data has poised this market to exhibit potentially high-value avenues and opportunities for growth over the forecast period. The market growth is also being fueled by an increase in the global prevalence of cancer and the availability of sophisticated healthcare facilities. As per GLOBOCAN 2020, there have been 1,92,92,789 new cancer cases in 2020, with the number expected to rise to 2,88,87,940 by 2040. Such a substantial rise in the number of cancer cases is estimated to leverage cancer research which will eventually accelerate the NGS market growth.
The NGS diagnostic techniques have the potential to determine a virus's genomic sequence and aid scientists in their understanding of mutations. Furthermore, throughout the COVID-19 epidemic, governments across the globe have been collaborating with the corporate sector to introduce NGS technology to the market as a viable diagnostic tool. The US Food and Drug Administration granted Illumina Inc. a case of emergency use permit for the first COVID-19 diagnostic using the next-generation sequence technique in June 2020. The Illumina COVIDSeq Test for qualitative identification of SARS-CoV-2 RNA has been approved by the FDA. As a result, the usage of next-generation sequencing (NGS) technologies is projected to increase during the pandemic.
Next-generation Sequencing Market Report Highlights
- By application, the oncology segment held the largest revenue share of the market in 2021. The segment growth is prominently attributed to increasing in the prevalence of cancer and advancements in sequencing technologies
- The academic research segment is expected to grow lucratively over the forecast period due to an increase in application-based usage in these institutes and a rise in oncology research. In addition, advancements in R&D for therapeutics, oncology, and genomics research led to the growth of the market
- North America dominated the market in 2021, due to the presence of high R&D investment, and availability of technologically advanced healthcare research framework, the development of WGS in the region is also expected to serve as a critical factor for the growth of the North America NGS market throughout the forecast period
- In Asia Pacific, the market is expected to grow considerably during the forecast period owing to extensive developments in healthcare infrastructure, the positive approach of respective countries for adoption of advanced technologies, and the presence of key players
CHAPTER 1 RESEARCH METHODOLOGY & SCOPE
1.1 Information Procurement
1.1.1 Purchased database:
1.1.2 GVR’s internal database
1.1.3 Secondary sources:
1.1.4 Third Party Perspective:
1.1.5 Primary Research:
1.2 Information or Data Analysis
1.3 Market Formulation & Validation
1.4 Region Wise Market Calculation
1.4.1 Region wise market: Base estimates
1.4.2 Global market: CAGR calculation
1.4.3 Region based segment share calculation
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Outlook
CHAPTER 3 MARKET VARIABLES, TRENDS & SCOPE
3.1 Market Lineage Outlook
3.1.1 Parent market outlook
3.1.2 Related/ancillary market outlook
3.2 Cost Structure Analysis
3.3 User Perspective Analysis
3.3.1 Consumer behavior analysis
3.3.2 Market influencer analysis
3.4 Procedure Cost Analysis
3.5 List of Key End-users
3.6 Technology Overview
3.6.1 Technology timeline
3.7 Impact of COVID-19 Pandemic
3.7.1 Impact on the supply chain
3.7.2 Association of COVID-19 with next-generation sequencing
3.8 Market Segmentation & Scope
3.8.1 Market driver analysis
3.8.1.1 Exponentially decreasing costs for genetic sequencing
3.8.1.2 Development of companion diagnostics and personalized medicine
3.8.1.3 Rise in competition amongst prominent market entities
3.8.1.4 Rising clinical opportunity for NGS technology
3.8.1.5 Technological advancements in cloud computing and data integration
3.8.1.6 Growing healthcare expenditure supporting the development of effective PM diagnostic & therapeutic procedures for cancer
3.8.1.7 Increasing prevalence of cancer
3.8.2 Market restraint analysis
3.8.2.1 Lack of computational efficiency for data management
3.8.2.2 Non-value based NGS reimbursement policy and regulation status
3.8.2.3 Challenges associated with NGS implementation
3.9 Penetration & Growth Prospect Mapping for Applications, 2019
3.10 Penetration & Growth Prospect Mapping for Prominent Industry Players, 2019
3.11 NGS Platform Penetration Mapping, 2019
3.11.1 Next-generation sequencing reimbursement environment
3.11.2 Gap-fill approach for reimbursement of NGS tests
3.11.3 Role of the commercial payers
3.11.3.1 Payer perspectives for developing coverage policy for Next-Generation Tumor Sequencing Panels (NGTS)
3.11.3.2 Role of diagnostic laboratories and pathology centers
3.11.4 North America
3.11.4.1 U.S.
3.11.4.2 Canada
3.11.5 Europe
3.11.5.1 U.K.
3.11.5.2 Germany
3.11.5.3 Spain
3.11.6 Asia Pacific
3.11.7 Latin America
3.11.8 Middle East Africa
3.11.9 Next-Generation Sequencing Market: Regional Market Share, 2021
3.12 Next-Generation Sequencing Regulatory and Political Environment
3.12.1 Next-Generation Sequencing North America Regulatory and Political Landscape Analysis, 2021
3.12.1.1 U.S.
3.12.1.2 Canada
3.12.2 Next-Generation Sequencing Europe Regulatory and Political Landscape Analysis, 2021
3.12.2.1 U.K.
3.12.2.2 Germany
3.12.2.3 France
3.12.2.4 Spain
3.12.3 Next-Generation Sequencing Asia Pacific Regulatory and Political Landscape Analysis, 2021
3.12.3.1 Japan
3.12.3.2 China
3.12.4 Next-Generation Sequencing Latin America Regulatory and Political Landscape Analysis, 2021
3.12.4.1 Brazil
3.12.4.2 Mexico
3.12.4.3 Argentina
3.12.5 Next-Generation Sequencing Middle East & Africa Regulatory and Political Landscape Analysis, 2021
3.12.5.1 South Africa
3.12.5.2 Qatar
3.12.5.3 Kuwait
3.12.5.4 UAE
3.12.5.5 Saudi Arabia
3.13 Next-Generation Sequencing - SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
3.14 Industry Analysis - Porter’s
3.14.1 Major deals & strategic alliances analysis
3.14.1.1 Joint ventures
3.14.1.2 Mergers & acquisitions
3.14.1.3 Licensing & partnership
3.14.2 Technology collaborations
3.15 Market Entry Strategies
3.16 Case Studies
3.16.1 Impact of NGS on Treatment Selection in acute myeloid leukemia (AML)
CHAPTER 4 COMPETITIVE ANALYSIS
4.1 Recent Developments & Impact Analysis, by Key Market Participants
4.2 Company Categorization
4.3 Public Companies
4.3.1 List of key distributors and channel partners
4.3.1.1 Service providers, manufacturers, & suppliers of products
4.3.1.2 Key distributors and channel partners of Illumina
4.3.1.2.1 Americas (North, South, & Central America)
4.3.1.2.2 Europe
4.3.1.2.3 Asia/Central Pacific
4.3.1.2.4 Middle East & Africa
4.3.1.3 Service providers of ThermoFisher
4.3.1.3.1 North America
4.3.1.3.2 EMEA
4.3.1.3.3 Asia Pacific
4.3.2 Key customers
4.3.3 Key company market share analysis, 2019
4.3.3.1 Company size
4.3.3.2 Geographical presence
4.3.3.3 Product portfolio
4.3.4 Competitive dashboard analysis
4.3.5 Market differentiators
4.3.6 Private companies
4.3.6.1 List of emerging players
4.3.6.2 Funding outlook
4.3.6.3 Regional network map
4.3.6.4 Company market position analysis, 2019
4.3.6.5 List of suppliers
CHAPTER 5 NGS APPLICATION ESTIMATES & TREND ANALYSIS
5.1 Next-Generation Sequencing Market: Application Movement Analysis
5.2 Oncology
5.2.1 Global oncology market, 2018 - 2030 (USD Million)
5.2.2 Diagnostics and screening
5.2.2.1 Diagnostics and screening market, 2018 - 2030 (USD Million)
5.2.2.2 Oncology screening
5.2.2.2.1 Oncology screening market, 2018 - 2030 (USD Million)
5.2.2.2.2 Sporadic cancer screening market, 2018 - 2030 (USD Million)
5.2.2.2.3 Inherited cancer screening market, 2018 - 2030 (USD Million)
5.2.2.3 Companion diagnostics
5.2.2.3.1 Companion diagnostics market, 2018 - 2030 (USD Million)
5.2.2.4 Other diagnostics
5.2.2.4.1 Other diagnostics market, 2018 - 2030 (USD Million)
5.2.3 Research studies
5.2.3.1 Research studies market, 2018 - 2030 (USD Million)
5.3 Clinical Investigation
5.3.1 Global clinical investigation market, 2018 - 2030 (USD Million)
5.3.2 Infectious diseases
5.3.2.1 Global infectious diseases market, 2018 - 2030 (USD Million)
5.3.3 Inherited diseases
5.3.3.1 Global inherited diseases market, 2018 - 2030 (USD Million)
5.3.4 Idiopathic diseases
5.3.4.1 Global idiopathic diseases market, 2018 - 2030 (USD Million)
5.3.5 Non-communicable/other diseases
5.3.5.1 Global non-communicable/other diseases market, 2018 - 2030 (USD Million)
5.4 Reproductive Health
5.4.1 Global reproductive health market, 2018 - 2030 (USD Million)
5.4.2 NIPT
5.4.2.1 Global NIPT market, 2018 - 2030 (USD Million)
5.4.2.2 Aneuploidy
5.4.2.2.1 Global aneuploidy market, 2018 - 2030 (USD Million)
5.4.2.3 Microdeletions
5.4.2.3.1 Global microdeletions market, 2018 - 2030 (USD Million)
5.4.3 PGT
5.4.3.1 Global NGS PGT market, 2018 - 2030 (USD Million)
5.4.4 New-born/genetic screening
5.4.4.1 Global newborn/genetic screening market, 2018 - 2030 (USD Million)
5.4.5 Single gene analysis
5.4.5.1 Single gene analysis market, 2018 - 2030 (USD Million)
5.5 HLA Typing/Immune System Monitoring
5.5.1 Global HLA typing/immune system monitoring market, 2018 - 2030 (USD Million)
5.6 Metagenomics, Epidemiology & Drug Development
5.6.1 Global metagenomics, epidemiology & drug development market, 2018 - 2030 (USD Million)
5.7 Agrigenomics & Forensics
5.7.1 Global agrigenomics & forensics market, 2018 - 2030 (USD Million)
5.8 Consumer Genomics
5.8.1 Global consumer genomics market, 2018 - 2030 (USD Million)
CHAPTER 6 NGS TECHNOLOGY ESTIMATES & TREND ANALYSIS
6.1 Next-Generation Sequencing Market: Technology Movement Analysis
6.2 Whole Genome Sequencing
6.2.1 Global whole genome sequencing market, 2018 - 2030 (USD Million)
6.3 Whole Exome Sequencing
6.3.1 Global whole exome sequencing market, 2018 - 2030 (USD Million)
6.4 Targeted Sequencing & Resequencing
6.4.1 Global targeted sequencing & resequencing market, 2018 - 2030 (USD Million)
6.4.2 DNA-based targeted sequencing & resequencing
6.4.2.1 Global DNA-based targeted sequencing & resequencing market, 2018 - 2030 (USD Million)
6.4.3 RNA-based targeted sequencing & resequencing
6.4.3.1 Global RNA-based targeted sequencing & resequencing market, 2018 - 2030 (USD Million)
CHAPTER 7 NGS WORKFLOW ESTIMATES & TREND ANALYSIS
7.1 Next-Generation Sequencing Market: Workflow Movement Analysis
7.2 Pre-Sequencing
7.2.1 Global pre-sequencing market, 2018 - 2030 (USD Million)
7.2.2 NGS library preparation kits
7.2.2.1 Global NGS library preparation kits market, 2018 - 2030 (USD Million)
7.2.3 NGS semi-automated library preparation
7.2.3.1 Global NGS semi-automated library preparation market, 2018 - 2030 (USD Million)
7.2.4 NGS automated library preparation
7.2.4.1 Global NGS automated library preparation market, 2018 - 2030 (USD Million)
7.2.5 Clonal amplification
7.2.5.1 Global clonal amplification market, 2018 - 2030 (USD Million)
7.3 Sequencing
7.3.1 Global sequencing market, 2018 - 2030 (USD Million)
7.4 Data Analysis
7.4.1 Global data analysis market, 2018 - 2030 (USD Million)
7.4.2 NGS primary data analysis
7.4.2.1 Global NGS primary data analysis market, 2018 - 2030 (USD Million)
7.4.3 NGS secondary data analysis
7.4.3.1 Global NGS secondary data analysis market, 2018 - 2030 (USD Million)
7.4.4 NGS tertiary data analysis
7.4.4.1 Global NGS tertiary data analysis services market, 2018 - 2030 (USD Million)
CHAPTER 8 NGS END-USE ESTIMATES & TREND ANALYSIS
8.1 Next-Generation Sequencing Market: End-Use Movement Analysis
8.2 Academic Research
8.2.1 Global academic research market, 2018 - 2030 (USD Million)
8.3 Clinical Research
8.3.1 Global clinical research market, 2018 - 2030 (USD Million)
8.4 Hospitals & Clinics
8.4.1 Global hospitals & clinics market2018 - 2030 (USD Million)
8.5 Pharma & Biotech Entities
8.5.1 Global pharma & biotech entities market, 2018 - 2030 (USD Million)
8.6 Other Users
8.6.1 Global other users market, 2018 - 2030 (USD Million)
CHAPTER 9 NGS REGIONAL ESTIMATES & TREND ANALYSIS, BY PRODUCT & SERVICE TYPE, APPLICATION, TECHNOLOGY, WORKFLOW, & END-USE
9.1 Next generation sequencing market share by region, 2019 & 2027
9.2 Regional Market Share and Leading Players, 2019
9.3 North America
9.3.1 North America next-generation sequencing market, 2018 - 2030 (USD Million)
9.3.2 U.S.
9.3.2.1 U.S. next-generation sequencing market, 2018 - 2030 (USD Million)
9.3.3 Canada
9.3.3.1 Canada next-generation sequencing market, 2018 - 2030 (USD Million)
9.4 Europe
9.4.1 Europe next-generation sequencing market, 2018 - 2030 (USD Million)
9.4.2 Germany
9.4.2.1 Germany next-generation sequencing market, 2018 - 2030 (USD Million)
9.4.3 U.K.
9.4.3.1 U.K. next-generation sequencing market, 2018 - 2030 (USD Million)
9.4.4 France
9.4.4.1 France next-generation sequencing market, 2018 - 2030 (USD Million)
9.4.5 Spain
9.4.5.1 Spain next-generation sequencing market, 2018 - 2030 (USD Million)
9.4.6 Italy
9.4.6.1 Italy next-generation sequencing market, 2018 - 2030 (USD Million)
9.5 Asia Pacific
9.5.1 Asia Pacific next-generation sequencing market, 2018 - 2030 (USD Million)
9.5.2 Japan
9.5.2.1 Japan next-generation sequencing market, 2018 - 2030 (USD Million)
9.5.3 China
9.5.3.1 China next-generation sequencing market, 2018 - 2030 (USD Million)
9.5.4 India
9.5.4.1 India next-generation sequencing market, 2018 - 2030 (USD Million)
9.5.5 Australia
9.5.5.1 Australia next-generation sequencing market, 2018 - 2030 (USD Million)
9.5.6 South Korea
9.5.6.1 South Korea next-generation sequencing market, 2018 - 2030 (USD Million)
9.6 Latin America
9.6.1 Latin America next-generation sequencing market, 2018 - 2030 (USD Million)
9.6.2 Brazil
9.6.2.1 Brazil next-generation sequencing market, 2018 - 2030 (USD Million)
9.6.3 Mexico
9.6.3.1 Mexico next-generation sequencing market, 2018 - 2030 (USD Million)
9.7 Middle East & Africa
9.7.1 Middle East & Africa next-generation sequencing market, 2018 - 2030 (USD Million)
9.7.2 South Africa
9.7.2.1 South Africa next-generation sequencing market, 2018 - 2030 (USD Million)
9.7.3 Saudi Arabia
9.7.3.1 Saudi Arabia next-generation sequencing market, 2018 - 2030 (USD Million)
CHAPTER 10 COMPETITIVE LANDSCAPE
10.1. Strategy Framework
10.2. Market Participation Categorization
10.3. Next-Generation Sequencing Vendor’s Landscape
10.4. Champions
10.5. Innovators
10.6. Emerging players
10.7. Market pillars
10.8. Company Profiles
10.8.1 Illumina, Inc.
10.8.1.1 Company overview
10.8.1.2 Financial performance
10.8.1.3 Product benchmarking
10.8.1.4 Strategic initiatives
10.8.2 F. Hoffmann-La Roche Ltd.
10.8.2.1 Company overview
10.8.2.2 Financial performance
10.8.2.3 Product benchmarking
10.8.2.4 Strategic initiatives
10.8.3 Agilent Technologies, Inc.
10.8.3.1 Company overview
10.8.3.2 Financial performance
10.8.3.3 Product benchmarking
10.8.3.4 Strategic initiatives
10.8.4 PierianDx
10.8.4.1 Company overview
10.8.5 Tute Genomics
10.8.5.1 Company overview
10.8.6 Knome, Inc.
10.8.6.1 Company overview
10.8.6.2 Financial performance
10.8.6.3 Product benchmarking
10.8.6.4 Strategic initiatives
10.8.7 Intrexon Bioinformatics Germany GmbH
10.8.7.1 Company overview
10.8.7.2 Financial performance
10.8.7.3 Product benchmarking
10.8.7.4 Strategic initiatives
10.8.8 Eurofins Scientific
10.8.8.1 Company overview
10.8.8.2 Eurofins GATC Biotech GmbH
10.8.8.2.1 Company overview
10.8.8.3 Financial performance
10.8.8.3.1 Financial performance: Eurofins GATC Biotech GmbH
10.8.8.4 Product benchmarking
10.8.8.5 Strategic initiatives
10.8.9 Oxford Nanopore Technologies
10.8.9.1 Company overview
10.8.9.2 Financial performance
10.8.9.3 Product benchmarking
10.8.9.4 Strategic initiatives
10.8.10 Macrogen, Inc.
10.8.10.1 Company overview
10.8.10.2 Financial performance
10.8.10.3 Product benchmarking
10.8.10.4 Strategic initiatives
10.8.11 DNASTAR, Inc.
10.8.11.1 Company overview
10.8.11.2 Financial Performance
10.8.11.3 Product benchmarking
10.8.11.4 Strategic initiatives
10.8.12 Thermo Fisher Scientific, Inc.
10.8.12.1 Company overview
10.8.12.1.1 Life Technologies Corp.
10.8.12.2 Financial performance
10.8.12.3 Product benchmarking
10.8.12.4 Strategic initiatives
10.8.13 Biomatters Ltd.
10.8.13.1 Company overview
10.8.13.2 Financial performance
10.8.13.3 Product benchmarking
10.8.13.4 Strategic initiatives
10.8.14 QIAGEN
10.8.13 Ingenuity
10.8.14 CLC Bio
10.8.14.1 Company overview
10.8.14.2 Financial performance
10.8.14.2 Financial performance
10.8.14.3 Product benchmarking
10.8.14.4 Strategic initiatives
10.8.15 BGI
10.8.15.1 Complete Genomics Incorporated
10.8.15.1.1 Company overview
10.8.15.1.2 Financial performance
10.8.15.1.3 Product benchmarking
10.8.15.1.4 Strategic initiatives
10.8.16 Perkin Elmer, Inc.
10.8.16.1 Company overview
10.8.16.2 PERKINELMER GENOMICS
10.8.16.3 Financial performance
10.8.16.4 Product benchmarking
10.8.16.5 Strategic initiatives
10.8.17 Pacific Biosciences of California, Inc.
10.8.17.1 Company overview
10.8.17.2 Financial performance
10.8.17.3 Product benchmarking
10.8.17.4 Strategic initiatives
10.8.18 Partek Incorporated
10.8.18.1 Company overview
10.8.18.2 Financial performance
10.8.18.3 Product benchmarking
10.8.18.4 Strategic initiatives
10.8.19 Bio-Rad Laboratories, Inc.
10.8.19.1 Company overview
10.8.20 GnuBio
10.8.20.1 Company overview
10.8.20.2 Financial performance
10.8.20.3 Product benchmarking
10.8.20.4 Strategic initiatives
10.8.21 Myriad Genetics, Inc.
10.8.21.1 Company overview
10.8.21.2 Financial performance
10.8.21.3 Product benchmarking
10.8.21.4 Strategic initiatives
10.8.22 Hologic, Inc. (Gen-Probe Incorporated)
10.8.22.1 Company overview
10.8.22.2 Financial performance
10.8.22.3 Product benchmarking
10.8.22.4 Strategic initiatives
10.8.23 Horizon Discovery Group plc
10.8.23.1 Company overview
10.8.23.2 Financial performance
10.8.23.3 Product benchmarking
10.8.23.4 Strategic initiatives
10.8.24 LGC Limited
10.8.24.1 Company overview
10.8.25 SeraCare
10.8.25.1 Company overview
10.8.25.2 Financial performance (LGC Limited)
10.8.25.3 Product benchmarking
10.8.25.4 Strategic initiatives
10.8.26 Vela Diagnostics
10.8.26.1 Company overview
10.8.26.2 Financial performance
10.8.26.3 Product benchmarking
10.8.26.4 Strategic initiatives
1.1 Information Procurement
1.1.1 Purchased database:
1.1.2 GVR’s internal database
1.1.3 Secondary sources:
1.1.4 Third Party Perspective:
1.1.5 Primary Research:
1.2 Information or Data Analysis
1.3 Market Formulation & Validation
1.4 Region Wise Market Calculation
1.4.1 Region wise market: Base estimates
1.4.2 Global market: CAGR calculation
1.4.3 Region based segment share calculation
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Outlook
CHAPTER 3 MARKET VARIABLES, TRENDS & SCOPE
3.1 Market Lineage Outlook
3.1.1 Parent market outlook
3.1.2 Related/ancillary market outlook
3.2 Cost Structure Analysis
3.3 User Perspective Analysis
3.3.1 Consumer behavior analysis
3.3.2 Market influencer analysis
3.4 Procedure Cost Analysis
3.5 List of Key End-users
3.6 Technology Overview
3.6.1 Technology timeline
3.7 Impact of COVID-19 Pandemic
3.7.1 Impact on the supply chain
3.7.2 Association of COVID-19 with next-generation sequencing
3.8 Market Segmentation & Scope
3.8.1 Market driver analysis
3.8.1.1 Exponentially decreasing costs for genetic sequencing
3.8.1.2 Development of companion diagnostics and personalized medicine
3.8.1.3 Rise in competition amongst prominent market entities
3.8.1.4 Rising clinical opportunity for NGS technology
3.8.1.5 Technological advancements in cloud computing and data integration
3.8.1.6 Growing healthcare expenditure supporting the development of effective PM diagnostic & therapeutic procedures for cancer
3.8.1.7 Increasing prevalence of cancer
3.8.2 Market restraint analysis
3.8.2.1 Lack of computational efficiency for data management
3.8.2.2 Non-value based NGS reimbursement policy and regulation status
3.8.2.3 Challenges associated with NGS implementation
3.9 Penetration & Growth Prospect Mapping for Applications, 2019
3.10 Penetration & Growth Prospect Mapping for Prominent Industry Players, 2019
3.11 NGS Platform Penetration Mapping, 2019
3.11.1 Next-generation sequencing reimbursement environment
3.11.2 Gap-fill approach for reimbursement of NGS tests
3.11.3 Role of the commercial payers
3.11.3.1 Payer perspectives for developing coverage policy for Next-Generation Tumor Sequencing Panels (NGTS)
3.11.3.2 Role of diagnostic laboratories and pathology centers
3.11.4 North America
3.11.4.1 U.S.
3.11.4.2 Canada
3.11.5 Europe
3.11.5.1 U.K.
3.11.5.2 Germany
3.11.5.3 Spain
3.11.6 Asia Pacific
3.11.7 Latin America
3.11.8 Middle East Africa
3.11.9 Next-Generation Sequencing Market: Regional Market Share, 2021
3.12 Next-Generation Sequencing Regulatory and Political Environment
3.12.1 Next-Generation Sequencing North America Regulatory and Political Landscape Analysis, 2021
3.12.1.1 U.S.
3.12.1.2 Canada
3.12.2 Next-Generation Sequencing Europe Regulatory and Political Landscape Analysis, 2021
3.12.2.1 U.K.
3.12.2.2 Germany
3.12.2.3 France
3.12.2.4 Spain
3.12.3 Next-Generation Sequencing Asia Pacific Regulatory and Political Landscape Analysis, 2021
3.12.3.1 Japan
3.12.3.2 China
3.12.4 Next-Generation Sequencing Latin America Regulatory and Political Landscape Analysis, 2021
3.12.4.1 Brazil
3.12.4.2 Mexico
3.12.4.3 Argentina
3.12.5 Next-Generation Sequencing Middle East & Africa Regulatory and Political Landscape Analysis, 2021
3.12.5.1 South Africa
3.12.5.2 Qatar
3.12.5.3 Kuwait
3.12.5.4 UAE
3.12.5.5 Saudi Arabia
3.13 Next-Generation Sequencing - SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
3.14 Industry Analysis - Porter’s
3.14.1 Major deals & strategic alliances analysis
3.14.1.1 Joint ventures
3.14.1.2 Mergers & acquisitions
3.14.1.3 Licensing & partnership
3.14.2 Technology collaborations
3.15 Market Entry Strategies
3.16 Case Studies
3.16.1 Impact of NGS on Treatment Selection in acute myeloid leukemia (AML)
CHAPTER 4 COMPETITIVE ANALYSIS
4.1 Recent Developments & Impact Analysis, by Key Market Participants
4.2 Company Categorization
4.3 Public Companies
4.3.1 List of key distributors and channel partners
4.3.1.1 Service providers, manufacturers, & suppliers of products
4.3.1.2 Key distributors and channel partners of Illumina
4.3.1.2.1 Americas (North, South, & Central America)
4.3.1.2.2 Europe
4.3.1.2.3 Asia/Central Pacific
4.3.1.2.4 Middle East & Africa
4.3.1.3 Service providers of ThermoFisher
4.3.1.3.1 North America
4.3.1.3.2 EMEA
4.3.1.3.3 Asia Pacific
4.3.2 Key customers
4.3.3 Key company market share analysis, 2019
4.3.3.1 Company size
4.3.3.2 Geographical presence
4.3.3.3 Product portfolio
4.3.4 Competitive dashboard analysis
4.3.5 Market differentiators
4.3.6 Private companies
4.3.6.1 List of emerging players
4.3.6.2 Funding outlook
4.3.6.3 Regional network map
4.3.6.4 Company market position analysis, 2019
4.3.6.5 List of suppliers
CHAPTER 5 NGS APPLICATION ESTIMATES & TREND ANALYSIS
5.1 Next-Generation Sequencing Market: Application Movement Analysis
5.2 Oncology
5.2.1 Global oncology market, 2018 - 2030 (USD Million)
5.2.2 Diagnostics and screening
5.2.2.1 Diagnostics and screening market, 2018 - 2030 (USD Million)
5.2.2.2 Oncology screening
5.2.2.2.1 Oncology screening market, 2018 - 2030 (USD Million)
5.2.2.2.2 Sporadic cancer screening market, 2018 - 2030 (USD Million)
5.2.2.2.3 Inherited cancer screening market, 2018 - 2030 (USD Million)
5.2.2.3 Companion diagnostics
5.2.2.3.1 Companion diagnostics market, 2018 - 2030 (USD Million)
5.2.2.4 Other diagnostics
5.2.2.4.1 Other diagnostics market, 2018 - 2030 (USD Million)
5.2.3 Research studies
5.2.3.1 Research studies market, 2018 - 2030 (USD Million)
5.3 Clinical Investigation
5.3.1 Global clinical investigation market, 2018 - 2030 (USD Million)
5.3.2 Infectious diseases
5.3.2.1 Global infectious diseases market, 2018 - 2030 (USD Million)
5.3.3 Inherited diseases
5.3.3.1 Global inherited diseases market, 2018 - 2030 (USD Million)
5.3.4 Idiopathic diseases
5.3.4.1 Global idiopathic diseases market, 2018 - 2030 (USD Million)
5.3.5 Non-communicable/other diseases
5.3.5.1 Global non-communicable/other diseases market, 2018 - 2030 (USD Million)
5.4 Reproductive Health
5.4.1 Global reproductive health market, 2018 - 2030 (USD Million)
5.4.2 NIPT
5.4.2.1 Global NIPT market, 2018 - 2030 (USD Million)
5.4.2.2 Aneuploidy
5.4.2.2.1 Global aneuploidy market, 2018 - 2030 (USD Million)
5.4.2.3 Microdeletions
5.4.2.3.1 Global microdeletions market, 2018 - 2030 (USD Million)
5.4.3 PGT
5.4.3.1 Global NGS PGT market, 2018 - 2030 (USD Million)
5.4.4 New-born/genetic screening
5.4.4.1 Global newborn/genetic screening market, 2018 - 2030 (USD Million)
5.4.5 Single gene analysis
5.4.5.1 Single gene analysis market, 2018 - 2030 (USD Million)
5.5 HLA Typing/Immune System Monitoring
5.5.1 Global HLA typing/immune system monitoring market, 2018 - 2030 (USD Million)
5.6 Metagenomics, Epidemiology & Drug Development
5.6.1 Global metagenomics, epidemiology & drug development market, 2018 - 2030 (USD Million)
5.7 Agrigenomics & Forensics
5.7.1 Global agrigenomics & forensics market, 2018 - 2030 (USD Million)
5.8 Consumer Genomics
5.8.1 Global consumer genomics market, 2018 - 2030 (USD Million)
CHAPTER 6 NGS TECHNOLOGY ESTIMATES & TREND ANALYSIS
6.1 Next-Generation Sequencing Market: Technology Movement Analysis
6.2 Whole Genome Sequencing
6.2.1 Global whole genome sequencing market, 2018 - 2030 (USD Million)
6.3 Whole Exome Sequencing
6.3.1 Global whole exome sequencing market, 2018 - 2030 (USD Million)
6.4 Targeted Sequencing & Resequencing
6.4.1 Global targeted sequencing & resequencing market, 2018 - 2030 (USD Million)
6.4.2 DNA-based targeted sequencing & resequencing
6.4.2.1 Global DNA-based targeted sequencing & resequencing market, 2018 - 2030 (USD Million)
6.4.3 RNA-based targeted sequencing & resequencing
6.4.3.1 Global RNA-based targeted sequencing & resequencing market, 2018 - 2030 (USD Million)
CHAPTER 7 NGS WORKFLOW ESTIMATES & TREND ANALYSIS
7.1 Next-Generation Sequencing Market: Workflow Movement Analysis
7.2 Pre-Sequencing
7.2.1 Global pre-sequencing market, 2018 - 2030 (USD Million)
7.2.2 NGS library preparation kits
7.2.2.1 Global NGS library preparation kits market, 2018 - 2030 (USD Million)
7.2.3 NGS semi-automated library preparation
7.2.3.1 Global NGS semi-automated library preparation market, 2018 - 2030 (USD Million)
7.2.4 NGS automated library preparation
7.2.4.1 Global NGS automated library preparation market, 2018 - 2030 (USD Million)
7.2.5 Clonal amplification
7.2.5.1 Global clonal amplification market, 2018 - 2030 (USD Million)
7.3 Sequencing
7.3.1 Global sequencing market, 2018 - 2030 (USD Million)
7.4 Data Analysis
7.4.1 Global data analysis market, 2018 - 2030 (USD Million)
7.4.2 NGS primary data analysis
7.4.2.1 Global NGS primary data analysis market, 2018 - 2030 (USD Million)
7.4.3 NGS secondary data analysis
7.4.3.1 Global NGS secondary data analysis market, 2018 - 2030 (USD Million)
7.4.4 NGS tertiary data analysis
7.4.4.1 Global NGS tertiary data analysis services market, 2018 - 2030 (USD Million)
CHAPTER 8 NGS END-USE ESTIMATES & TREND ANALYSIS
8.1 Next-Generation Sequencing Market: End-Use Movement Analysis
8.2 Academic Research
8.2.1 Global academic research market, 2018 - 2030 (USD Million)
8.3 Clinical Research
8.3.1 Global clinical research market, 2018 - 2030 (USD Million)
8.4 Hospitals & Clinics
8.4.1 Global hospitals & clinics market2018 - 2030 (USD Million)
8.5 Pharma & Biotech Entities
8.5.1 Global pharma & biotech entities market, 2018 - 2030 (USD Million)
8.6 Other Users
8.6.1 Global other users market, 2018 - 2030 (USD Million)
CHAPTER 9 NGS REGIONAL ESTIMATES & TREND ANALYSIS, BY PRODUCT & SERVICE TYPE, APPLICATION, TECHNOLOGY, WORKFLOW, & END-USE
9.1 Next generation sequencing market share by region, 2019 & 2027
9.2 Regional Market Share and Leading Players, 2019
9.3 North America
9.3.1 North America next-generation sequencing market, 2018 - 2030 (USD Million)
9.3.2 U.S.
9.3.2.1 U.S. next-generation sequencing market, 2018 - 2030 (USD Million)
9.3.3 Canada
9.3.3.1 Canada next-generation sequencing market, 2018 - 2030 (USD Million)
9.4 Europe
9.4.1 Europe next-generation sequencing market, 2018 - 2030 (USD Million)
9.4.2 Germany
9.4.2.1 Germany next-generation sequencing market, 2018 - 2030 (USD Million)
9.4.3 U.K.
9.4.3.1 U.K. next-generation sequencing market, 2018 - 2030 (USD Million)
9.4.4 France
9.4.4.1 France next-generation sequencing market, 2018 - 2030 (USD Million)
9.4.5 Spain
9.4.5.1 Spain next-generation sequencing market, 2018 - 2030 (USD Million)
9.4.6 Italy
9.4.6.1 Italy next-generation sequencing market, 2018 - 2030 (USD Million)
9.5 Asia Pacific
9.5.1 Asia Pacific next-generation sequencing market, 2018 - 2030 (USD Million)
9.5.2 Japan
9.5.2.1 Japan next-generation sequencing market, 2018 - 2030 (USD Million)
9.5.3 China
9.5.3.1 China next-generation sequencing market, 2018 - 2030 (USD Million)
9.5.4 India
9.5.4.1 India next-generation sequencing market, 2018 - 2030 (USD Million)
9.5.5 Australia
9.5.5.1 Australia next-generation sequencing market, 2018 - 2030 (USD Million)
9.5.6 South Korea
9.5.6.1 South Korea next-generation sequencing market, 2018 - 2030 (USD Million)
9.6 Latin America
9.6.1 Latin America next-generation sequencing market, 2018 - 2030 (USD Million)
9.6.2 Brazil
9.6.2.1 Brazil next-generation sequencing market, 2018 - 2030 (USD Million)
9.6.3 Mexico
9.6.3.1 Mexico next-generation sequencing market, 2018 - 2030 (USD Million)
9.7 Middle East & Africa
9.7.1 Middle East & Africa next-generation sequencing market, 2018 - 2030 (USD Million)
9.7.2 South Africa
9.7.2.1 South Africa next-generation sequencing market, 2018 - 2030 (USD Million)
9.7.3 Saudi Arabia
9.7.3.1 Saudi Arabia next-generation sequencing market, 2018 - 2030 (USD Million)
CHAPTER 10 COMPETITIVE LANDSCAPE
10.1. Strategy Framework
10.2. Market Participation Categorization
10.3. Next-Generation Sequencing Vendor’s Landscape
10.4. Champions
10.5. Innovators
10.6. Emerging players
10.7. Market pillars
10.8. Company Profiles
10.8.1 Illumina, Inc.
10.8.1.1 Company overview
10.8.1.2 Financial performance
10.8.1.3 Product benchmarking
10.8.1.4 Strategic initiatives
10.8.2 F. Hoffmann-La Roche Ltd.
10.8.2.1 Company overview
10.8.2.2 Financial performance
10.8.2.3 Product benchmarking
10.8.2.4 Strategic initiatives
10.8.3 Agilent Technologies, Inc.
10.8.3.1 Company overview
10.8.3.2 Financial performance
10.8.3.3 Product benchmarking
10.8.3.4 Strategic initiatives
10.8.4 PierianDx
10.8.4.1 Company overview
10.8.5 Tute Genomics
10.8.5.1 Company overview
10.8.6 Knome, Inc.
10.8.6.1 Company overview
10.8.6.2 Financial performance
10.8.6.3 Product benchmarking
10.8.6.4 Strategic initiatives
10.8.7 Intrexon Bioinformatics Germany GmbH
10.8.7.1 Company overview
10.8.7.2 Financial performance
10.8.7.3 Product benchmarking
10.8.7.4 Strategic initiatives
10.8.8 Eurofins Scientific
10.8.8.1 Company overview
10.8.8.2 Eurofins GATC Biotech GmbH
10.8.8.2.1 Company overview
10.8.8.3 Financial performance
10.8.8.3.1 Financial performance: Eurofins GATC Biotech GmbH
10.8.8.4 Product benchmarking
10.8.8.5 Strategic initiatives
10.8.9 Oxford Nanopore Technologies
10.8.9.1 Company overview
10.8.9.2 Financial performance
10.8.9.3 Product benchmarking
10.8.9.4 Strategic initiatives
10.8.10 Macrogen, Inc.
10.8.10.1 Company overview
10.8.10.2 Financial performance
10.8.10.3 Product benchmarking
10.8.10.4 Strategic initiatives
10.8.11 DNASTAR, Inc.
10.8.11.1 Company overview
10.8.11.2 Financial Performance
10.8.11.3 Product benchmarking
10.8.11.4 Strategic initiatives
10.8.12 Thermo Fisher Scientific, Inc.
10.8.12.1 Company overview
10.8.12.1.1 Life Technologies Corp.
10.8.12.2 Financial performance
10.8.12.3 Product benchmarking
10.8.12.4 Strategic initiatives
10.8.13 Biomatters Ltd.
10.8.13.1 Company overview
10.8.13.2 Financial performance
10.8.13.3 Product benchmarking
10.8.13.4 Strategic initiatives
10.8.14 QIAGEN
10.8.13 Ingenuity
10.8.14 CLC Bio
10.8.14.1 Company overview
10.8.14.2 Financial performance
10.8.14.2 Financial performance
10.8.14.3 Product benchmarking
10.8.14.4 Strategic initiatives
10.8.15 BGI
10.8.15.1 Complete Genomics Incorporated
10.8.15.1.1 Company overview
10.8.15.1.2 Financial performance
10.8.15.1.3 Product benchmarking
10.8.15.1.4 Strategic initiatives
10.8.16 Perkin Elmer, Inc.
10.8.16.1 Company overview
10.8.16.2 PERKINELMER GENOMICS
10.8.16.3 Financial performance
10.8.16.4 Product benchmarking
10.8.16.5 Strategic initiatives
10.8.17 Pacific Biosciences of California, Inc.
10.8.17.1 Company overview
10.8.17.2 Financial performance
10.8.17.3 Product benchmarking
10.8.17.4 Strategic initiatives
10.8.18 Partek Incorporated
10.8.18.1 Company overview
10.8.18.2 Financial performance
10.8.18.3 Product benchmarking
10.8.18.4 Strategic initiatives
10.8.19 Bio-Rad Laboratories, Inc.
10.8.19.1 Company overview
10.8.20 GnuBio
10.8.20.1 Company overview
10.8.20.2 Financial performance
10.8.20.3 Product benchmarking
10.8.20.4 Strategic initiatives
10.8.21 Myriad Genetics, Inc.
10.8.21.1 Company overview
10.8.21.2 Financial performance
10.8.21.3 Product benchmarking
10.8.21.4 Strategic initiatives
10.8.22 Hologic, Inc. (Gen-Probe Incorporated)
10.8.22.1 Company overview
10.8.22.2 Financial performance
10.8.22.3 Product benchmarking
10.8.22.4 Strategic initiatives
10.8.23 Horizon Discovery Group plc
10.8.23.1 Company overview
10.8.23.2 Financial performance
10.8.23.3 Product benchmarking
10.8.23.4 Strategic initiatives
10.8.24 LGC Limited
10.8.24.1 Company overview
10.8.25 SeraCare
10.8.25.1 Company overview
10.8.25.2 Financial performance (LGC Limited)
10.8.25.3 Product benchmarking
10.8.25.4 Strategic initiatives
10.8.26 Vela Diagnostics
10.8.26.1 Company overview
10.8.26.2 Financial performance
10.8.26.3 Product benchmarking
10.8.26.4 Strategic initiatives
LIST OF TABLES
TABLE 1 List of Secondary Sources
TABLE 2 Country share estimation
TABLE 3 Healthcare expenditure, 2015
TABLE 4 NGS top platforms
TABLE 5 Base pairs sequenced using WGS, WES, and targeted sequencing & resequencing
TABLE 6 Clonal amplification products in the market
TABLE 7 North America next generation sequencing market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 8 North America next generation sequencing for oncology market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 9 North America next generation sequencing for oncology diagnostics & screening market, by application, 2018 - 2030 (USD Million)
TABLE 10 North America next generation sequencing for oncology screening market, by application, 2018 - 2030 (USD Million)
TABLE 11 North America NGS clinical investigation market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 12 North America NGS reproductive health market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 13 North America next generation sequencing NIPT market, by application, 2018 - 2030 (USD Million)
TABLE 14 North America next generation sequencing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
TABLE 15 North America targeted sequencing/resequencing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
TABLE 16 North America next generation sequencing market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
TABLE 17 North America NGS pre-sequencing market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
TABLE 18 North America NGS data analysis market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
TABLE 19 North America next generation sequencing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
TABLE 20 U.S. next generation sequencing market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 21 U.S. next generation sequencing for oncology market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 22 U.S. next generation sequencing for oncology diagnostics & screening market, by application, 2018 - 2030 (USD Million)
TABLE 23 U.S. next generation sequencing for oncology screening market, by application, 2018 - 2030 (USD Million)
TABLE 24 U.S. NGS clinical investigation market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 25 U.S. NGS reproductive health market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 26 U.S. next generation sequencing NIPT market, by application, 2018 - 2030 (USD Million)
TABLE 27 U.S. next generation sequencing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
TABLE 28 U.S. targeted sequencing/resequencing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
TABLE 29 U.S. next generation sequencing market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
TABLE 30 U.S. NGS pre-sequencing market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
TABLE 31 U.S. NGS data analysis market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
TABLE 32 U.S. next generation sequencing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
TABLE 33 Canada next generation sequencing market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 34 Canada next generation sequencing for oncology market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 35 Canada next generation sequencing for oncology diagnostics & screening market, by application, 2018 - 2030 (USD Million)
TABLE 36 Canada next generation sequencing for oncology screening market, by application, 2018 - 2030 (USD Million)
TABLE 37 Canada NGS clinical investigation market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 38 Canada NGS reproductive health market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 39 Canada next generation sequencing NIPT market, by application, 2018 - 2030 (USD Million)
TABLE 40 Canada next generation sequencing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
TABLE 41 Canada targeted sequencing/resequencing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
TABLE 42 Canada next generation sequencing market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
TABLE 43 Canada NGS pre-sequencing market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
TABLE 44 Canada NGS data analysis market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
TABLE 45 Canada next generation sequencing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
TABLE 46 Europe next generation sequencing market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 47 Europe next generation sequencing for oncology market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 48 Europe next generation sequencing for oncology diagnostics & screening market, by application, 2018 - 2030 (USD Million)
TABLE 49 Europe next generation sequencing for oncology screening market, by application, 2018 - 2030 (USD Million)
TABLE 50 Europe NGS clinical investigation market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 51 Europe NGS reproductive health market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 52 Europe next generation sequencing NIPT market, by application, 2018 - 2030 (USD Million)
TABLE 53 Europe next generation sequencing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
TABLE 54 Europe targeted sequencing/resequencing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
TABLE 55 Europe next generation sequencing market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
TABLE 56 Europe NGS pre-sequencing market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
TABLE 57 Europe NGS data analysis market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
TABLE 58 Europe next generation sequencing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
TABLE 59 Germany next generation sequencing market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 60 Germany next generation sequencing for oncology market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 61 Germany next generation sequencing for oncology diagnostics & screening market, by application, 2018 - 2030 (USD Million)
TABLE 62 Germany next generation sequencing for oncology screening market, by application, 2018 - 2030 (USD Million)
TABLE 63 Germany NGS clinical investigation market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 64 Germany NGS reproductive health market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 65 Germany next generation sequencing NIPT market, by application, 2018 - 2030 (USD Million)
TABLE 66 Germany next generation sequencing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
TABLE 67 Germany targeted sequencing/resequencing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
TABLE 68 Germany next generation sequencing market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
TABLE 69 Germany NGS pre-sequencing market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
TABLE 70 Germany NGS data analysis market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
TABLE 71 Germany next generation sequencing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
TABLE 72 U.K. next generation sequencing market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 73 U.K. next generation sequencing for oncology market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 74 U.K. next generation sequencing for oncology diagnostics & screening market, by application, 2018 - 2030 (USD Million)
TABLE 75 U.K. next generation sequencing for oncology screening market, by application, 2018 - 2030 (USD Million)
TABLE 76 U.K. NGS clinical investigation market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 77 U.K. NGS reproductive health market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 78 U.K. next generation sequencing NIPT market, by application, 2018 - 2030 (USD Million)
TABLE 79 U.K. next generation sequencing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
TABLE 80 U.K. targeted sequencing/resequencing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
TABLE 81 U.K. next generation sequencing market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
TABLE 82 U.K. NGS pre-sequencing market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
TABLE 83 U.K. NGS data analysis market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
TABLE 84 U.K. next generation sequencing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
TABLE 85 Spain next generation sequencing market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 86 Spain next generation sequencing for oncology market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 87 Spain next generation sequencing for oncology diagnostics & screening market, by application, 2018 - 2030 (USD Million)
TABLE 88 Spain next generation sequencing for oncology screening market, by application, 2018 - 2030 (USD Million)
TABLE 89 Spain NGS clinical investigation mark
TABLE 1 List of Secondary Sources
TABLE 2 Country share estimation
TABLE 3 Healthcare expenditure, 2015
TABLE 4 NGS top platforms
TABLE 5 Base pairs sequenced using WGS, WES, and targeted sequencing & resequencing
TABLE 6 Clonal amplification products in the market
TABLE 7 North America next generation sequencing market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 8 North America next generation sequencing for oncology market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 9 North America next generation sequencing for oncology diagnostics & screening market, by application, 2018 - 2030 (USD Million)
TABLE 10 North America next generation sequencing for oncology screening market, by application, 2018 - 2030 (USD Million)
TABLE 11 North America NGS clinical investigation market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 12 North America NGS reproductive health market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 13 North America next generation sequencing NIPT market, by application, 2018 - 2030 (USD Million)
TABLE 14 North America next generation sequencing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
TABLE 15 North America targeted sequencing/resequencing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
TABLE 16 North America next generation sequencing market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
TABLE 17 North America NGS pre-sequencing market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
TABLE 18 North America NGS data analysis market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
TABLE 19 North America next generation sequencing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
TABLE 20 U.S. next generation sequencing market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 21 U.S. next generation sequencing for oncology market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 22 U.S. next generation sequencing for oncology diagnostics & screening market, by application, 2018 - 2030 (USD Million)
TABLE 23 U.S. next generation sequencing for oncology screening market, by application, 2018 - 2030 (USD Million)
TABLE 24 U.S. NGS clinical investigation market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 25 U.S. NGS reproductive health market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 26 U.S. next generation sequencing NIPT market, by application, 2018 - 2030 (USD Million)
TABLE 27 U.S. next generation sequencing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
TABLE 28 U.S. targeted sequencing/resequencing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
TABLE 29 U.S. next generation sequencing market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
TABLE 30 U.S. NGS pre-sequencing market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
TABLE 31 U.S. NGS data analysis market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
TABLE 32 U.S. next generation sequencing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
TABLE 33 Canada next generation sequencing market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 34 Canada next generation sequencing for oncology market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 35 Canada next generation sequencing for oncology diagnostics & screening market, by application, 2018 - 2030 (USD Million)
TABLE 36 Canada next generation sequencing for oncology screening market, by application, 2018 - 2030 (USD Million)
TABLE 37 Canada NGS clinical investigation market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 38 Canada NGS reproductive health market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 39 Canada next generation sequencing NIPT market, by application, 2018 - 2030 (USD Million)
TABLE 40 Canada next generation sequencing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
TABLE 41 Canada targeted sequencing/resequencing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
TABLE 42 Canada next generation sequencing market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
TABLE 43 Canada NGS pre-sequencing market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
TABLE 44 Canada NGS data analysis market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
TABLE 45 Canada next generation sequencing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
TABLE 46 Europe next generation sequencing market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 47 Europe next generation sequencing for oncology market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 48 Europe next generation sequencing for oncology diagnostics & screening market, by application, 2018 - 2030 (USD Million)
TABLE 49 Europe next generation sequencing for oncology screening market, by application, 2018 - 2030 (USD Million)
TABLE 50 Europe NGS clinical investigation market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 51 Europe NGS reproductive health market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 52 Europe next generation sequencing NIPT market, by application, 2018 - 2030 (USD Million)
TABLE 53 Europe next generation sequencing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
TABLE 54 Europe targeted sequencing/resequencing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
TABLE 55 Europe next generation sequencing market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
TABLE 56 Europe NGS pre-sequencing market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
TABLE 57 Europe NGS data analysis market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
TABLE 58 Europe next generation sequencing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
TABLE 59 Germany next generation sequencing market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 60 Germany next generation sequencing for oncology market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 61 Germany next generation sequencing for oncology diagnostics & screening market, by application, 2018 - 2030 (USD Million)
TABLE 62 Germany next generation sequencing for oncology screening market, by application, 2018 - 2030 (USD Million)
TABLE 63 Germany NGS clinical investigation market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 64 Germany NGS reproductive health market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 65 Germany next generation sequencing NIPT market, by application, 2018 - 2030 (USD Million)
TABLE 66 Germany next generation sequencing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
TABLE 67 Germany targeted sequencing/resequencing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
TABLE 68 Germany next generation sequencing market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
TABLE 69 Germany NGS pre-sequencing market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
TABLE 70 Germany NGS data analysis market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
TABLE 71 Germany next generation sequencing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
TABLE 72 U.K. next generation sequencing market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 73 U.K. next generation sequencing for oncology market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 74 U.K. next generation sequencing for oncology diagnostics & screening market, by application, 2018 - 2030 (USD Million)
TABLE 75 U.K. next generation sequencing for oncology screening market, by application, 2018 - 2030 (USD Million)
TABLE 76 U.K. NGS clinical investigation market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 77 U.K. NGS reproductive health market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 78 U.K. next generation sequencing NIPT market, by application, 2018 - 2030 (USD Million)
TABLE 79 U.K. next generation sequencing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
TABLE 80 U.K. targeted sequencing/resequencing market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
TABLE 81 U.K. next generation sequencing market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
TABLE 82 U.K. NGS pre-sequencing market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
TABLE 83 U.K. NGS data analysis market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
TABLE 84 U.K. next generation sequencing market estimates & forecasts, by end-use, 2018 - 2030 (USD Million)
TABLE 85 Spain next generation sequencing market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 86 Spain next generation sequencing for oncology market estimates & forecasts, by application, 2018 - 2030 (USD Million)
TABLE 87 Spain next generation sequencing for oncology diagnostics & screening market, by application, 2018 - 2030 (USD Million)
TABLE 88 Spain next generation sequencing for oncology screening market, by application, 2018 - 2030 (USD Million)
TABLE 89 Spain NGS clinical investigation mark
